Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722239 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Commercial Insight: HIV - Change of Guard
Datamonitor, Dec 2006, Pages: 157


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral markets relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.

Scope of this title:

- In-depth analysis of the current HIV market across the major Western markets (US, France, Germany, Italy, Spain, UK)
- Thorough assessment of underlying commercial and clinical influencing factors shaping the antiretroviral market
- Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets
- Case study analysis of the competitive environment and critical success factors in the Protease Inhibitor class

Highlights of this title:

- By 2015 the global antibacterial market is forecast to be valued at more than $10 billion with a modest CAGR of 4.1%. The main contributor to growth will be the new drug classes such as integrase- and entry inhibitors.
- Since the advent of HAART, HIV has turned into a chronic disease with an average life expectancy similar to that of Type 2 diabetes, emphasizing the importance of side effect profiles associated with long-term use.
- The launch of several new products from new classes such as integrase inhibitors, CCR5 inhibitors from 2007, and recently launched PIs, will cause the salvage market to decline. Despite proven synergy between Fuzeon and the new drugs, use of the former is predicted to decline.

Reasons to order your copy:

- Understand the constantly evolving market dynamics of antiretroviral (ARV) drugs
- Explore the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies
- Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline ARVs from 2005 to 2015.



Customers who bought this item also bought

Commercial Insight: HIV - Reshaping Treatment Paradigms

Generic Benchmarking: Brand Erosion at Patent Expiry

Pipeline Insight: HIV - Enter the New Generation Inhibitors

Global HIV Market: An Analysis

Pipeline Insight: HIV - The Age of Convenience

Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion At Patent Expiry

HIV - Benchmarking Rapid Antiretroviral Uptake

The Global HIV/AIDS Market Outlook to 2012

HIV - Simplicity And Survival

Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need

Commercial Insight: HIV - Simplicity and Survival

Stakeholder Insight: HIV Therapy Dynamics



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds